Volume 3, Issue 2, June 2021

MutViz 2.0: visual analysis of somatic mutations and the impact of mutational signatures on selected genomic regions

• Abstracts
• View article
• Supplementary data

Inhibition of tryptophan 2,3-dioxygenase impairs DNA damage tolerance and repair in glioma cells

• Abstracts
• View article
• Supplementary data

Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs

• Abstracts
• View article
• Supplementary data

Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses

• Abstract
• View article
• Supplementary data

Homologous recombination, cancer and the ‘RAD51 paradox’

• Abstracts
• View article

Identification of combinations of somatic mutations that predict cancer survival and immunotherapy benefit

• Abstract
• View article
• Supplementary data

Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors

• Abstracts
• View article
• Supplementary data

A novel class of inhibitors that target SRSF10 and promote p53-mediated cytotoxicity on human colorectal cancer cells

• Abstracts
• View article
• Supplementary data

Correction to ‘Elucidation of the BMI1 interactome identifies novel regulatory roles in glioblastoma’

• Extract
• View article

Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity

• Abstracts
• View article
• Supplementary data

Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer

• Abstract
• View article
• Supplementary data

Reboot: a straightforward approach to identify genes and splicing isoforms associated with cancer patient prognosis

• Abstract
• View article
• Supplementary data

EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer

• Abstract
• View article
• Supplementary data